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Various treatments approved by the United States Food and Drug Administration for the
management of pulmonary arterial hypertension (PAH) target three of the many pathways
implicated in the development of PAH: prostacyclin-, endothelin-1 (ET-1)-, and nitric oxide-
mediated pathways. The objectives of this manuscript are to provide background information
on the role of ET-1 in the pathogenesis of PAH, to provide theoretical considerations for the
advantages and disadvantages of dual vs single endothelin receptor antagonists (ERAs) for
the management of PAH, and to describe the clinical study results from randomized,
double-blind, placebo-controlled trials for the various ERAs. ET receptors (ETA and ETB) have
different densities and distributions throughout the body and are dynamically regulated, such
that blockade of ETA and ETB receptors may have different results in normal vs pathological
conditions. Although differences in biological effects can be found in studies of isolated cells,
blood vessels and animal models, clinical treatment studies have not identified clear differ-
ences in efficacy among the various ERAs. The main differences appear to be in safety profiles,
with a greater frequency of serum liver function abnormalities occurring with the available
dual ETA/ETB antagonist, and possibly higher rates of peripheral edema noted with selective
ETA agents. Head-to-head studies will be necessary to resolve the question of whether single
vs dual blockade produces better clinical results with fewer side effects in patients with PAH.
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The treatment of pulmonary arterial hypertension (PAH)
improved in 1995 with the approval by the United States (US)
Food andDrugAdministration (FDA) of the prostacyclin analog
epoprostenol. This was followed in 2001 with FDA approval of
the dual endothelin receptor antagonist (ERA) bosentan. Two
more prostacyclin analogs were approved for use in the US,
treprostinil in 2002, and inhaled iloprost in 2004. The phos-
phodiesterase-5 (PDE-5) inhibitor sildenafil was approved in
2005, and the latest approval in 2007 was for ambrisentan,
another ERA. These different treatment options target 3
of the many pathways that have been implicated in the
development of PAH: prostacyclin-, endothelin-1 (ET-1)-, and
nitric oxide-mediated pathways.1 The objectives of this
manuscript are to provide background information on the role
of ET-1 in the pathogenesis of PAH, to provide theoretical
considerations for the advantages and disadvantages of
dual vs single ERAs for the management of PAH, and to
describe the clinical study results from randomized, double-
blind, placebo-controlled trials for the various ERAs.Endothelin
Historical perspective
ET was first reported in 1988 as a novel potent vasocon-
strictor peptide with a molecular weight of 2492 Da isolated
from porcine endothelial cells.2 The endothelins area family of isopeptides named ET-1, ET-2 and ET-3. ET-1 is
the most abundant and appears to be the most clinically
important form of endothelin. ET is synthesized from pre-
proendothelin (prepro-ET), comprised of 212 amino acids,
and is cleaved to yield a 38 amino acid propeptide, big ET
(Fig. 1). Big ET is converted to the 21 amino acid peptide ET
by endothelin-converting enzymes (ECEs).
Physiological/pathological role
The physiological and pathological roles of ET have been
examined by noting where overexpression of ET occurs and
by studying the effects of exogenously applied ET. For
example, overexpression of ET has been observed in tissue
samples from various disease states (PAH, connective tissue
disease, pulmonary fibrosis),3 and in the blood of systemic
sclerosis patients with either PH and/or lung fibrosis.4 In
a rat model of PAH induced by hypoxia, increased ET
expression was observed within the pulmonary artery but
not on the thoracic aorta, suggesting tissue selectivity in
the abnormal ET expression.5 Details of selected studies
examining different physiological and pathological effects
of ET are listed in Table 1.
Vasoconstriction
One of the first physiological properties of ET to be
observed was vasoconstriction, either as a direct effect on
the vasculature or indirectly as facilitated by other vaso-
constrictor systems (e.g., the renineangiotensin system or
the sympathetic nervous system). In studies conducted in
Figure 1 Regulation of ET-1 synthesis, pathway of ET generation and ET-receptor-mediated actions on smooth muscle cells.
Endothelin-1 (ET-1) synthesis is regulated by many factors; stimulators are highlighted in green, and inhibitors are highlighted in
red. The product of ET-1 transcription is prepro-ET-1, which is cleaved by a neutral endopeptidase to form the active precursor pro-
ET-1 or big ET-1. Big ET-1 is converted to the mature peptide by the metalloproteinase endothelin-converting enzyme-1 (ECE-1).
Two ET receptors have been identified in the vasculature: ET type-A receptors (ETA) reside in vascular smooth muscle cells
and mediate vasoconstriction and cell proliferation, whereas ETB receptors reside on endothelial cells and are mainly vasodilatory
through nitric oxide, and regulate the synthesis of ET-1. ETB receptors on smooth muscle cells can elicit vessel contraction.
CsA, cyclosporin A; EGF, epidermal growth factor; HGF, hepatocyte growth factor; IL-1, interleukin-1; LDL, low-density lipoprotein;
VEGF, vascular endothelial growth factor. Reprinted with permission from Macmillan Publishers Ltd: Nature Reviews Drug
Discovery (Remuzzi et al. New Therapeutics that antagonize endothelin: promises and frustrations. Nat Rev Drug Discov
2002;1(12):986e1001), copyright 2002.38
Endothelin receptor blockade 953anesthetized squirrel monkeys, ET was found to be more
potent and longer acting than angiotensin II in producing
vasoconstriction.6 Other studies have shown that ET-1 is 100
times more potent as a vasoconstrictor than pinephrine.2,7
Hypertrophy
Another physiological/pathological effect of ET is the
induction of hypertrophy in a variety of tissues, including
cardiomyocytes,8 cardiac fibroblasts, astrocytes, renal
interstitial fibroblasts and mesangial cells,9 vascular
smooth muscle cells,10 and fibroblasts.11 For example, in
one study conducted in cultured neonatal rat car-
diomyocytes, cell surface area more than doubled after
treatment with ET (107 M for 48 h) compared with
untreated cells, without a change in the number of car-
diomyocytes, consistent with cellular hypertrophy.8
Proliferation
ET can also cause proliferation of both vascular smooth
muscle cells and fibroblasts. For example, biologically
active ET in the bronchoalveolar lavage fluid from patients
with systemic sclerosis can stimulate the in vitroproliferation of cultured human fetal lung fibroblasts in
a dose-dependent manner.12 The in vitro proliferative
response of human aortic smooth muscle cell to stimulation
by platelet-derived growth factor is markedly potentiated
by ET.10
Inflammation
Another effect of ET is the induction of inflammation
through various mechanisms, including increased vascular
permeability, the stimulation of pro-inflammatory cytokine
production, activation of neutrophils or mast cells, and the
promotion of cellular adhesion. Infusion of ET (6 nmol/kg
i.v.) induces an inflammatory reaction in rat alveolar tissue
characterized by platelet aggregation, vascular congestion,
neutrophil activation and resultant endothelial cell injury
within the pulmonary circulation.13 In other experiments,
ET induces the secretion of interluekin-6 (an inflammatory
cytokine) from vascular smooth muscle cells isolated from
human saphenous veins.14 Finally, the intravenous admin-
istration of ET to guinea pigs (0.3 nmol/kg and 1 nmol/kg)
can increase vascular permeability as indicated by the
extravasation of albumin into the lung.15
Table 1 Selected references studying different pathological effects of endothelin (ET).
Pathological
effect
Reference Study design Result
Vasoconstriction Clozel and Clozel6 Anesthetized squirrel monkeys
were studied with Doppler
flow-probes to measure blood
flow in the renal, mesenteric
and iliac vascular beds with
application of ET.
All three vascular beds were constricted with i.v.
injection of ET. In the kidney, blood flow was almost
abolished and the effect of ET was sustained for up to
2 h and more.
Hypertrophy Ito et al.8 Cultured neonatal rat
cardiomyocytes were examined
by Northern blot analysis.
Cell surface area more than doubled after treatment
with ET (107 M for 48 h) compared with untreated
cells; however, the number of cardiomyocytes did not
change. These results suggest cardiac hypertrophy.
Proliferation Cambrey et al.12 Bronchoalveolar lavage fluid
was obtained from patients
with systemic sclerosis and
added to a culture of
fibroblasts.
Bronchoalveolar lavage fluid stimulated proliferation
of in vitro human fetal lung fibroblasts in a dose-
dependent manner.
Yang et al.10 Human aortic smooth muscle
cells were cultured and cell
proliferation was assayed by
[3H]thymidine incorporation.
ET was a co-mitogen because it markedly potentiated
the proliferative effects of platelet-derived growth
factor.
Inflammation Helset et al.13 The time sequence for
morphological changes induced
by ET-1 in rat alveolar tissue
was examined using
morphometric analysis based
on lung transmission electron
micrographs.
The following changes occurred in the pulmonary
circulation: platelet aggregation, vascular
congestion, and neutrophil activation leading to
endothelial cell injury. Morphological signs of injury
could be seen on the endothelial cells.
Browatzki et al.14 Confluent vascular smooth
muscle cells isolated from
human saphenous veins were
incubated with ET for 24 h.
ET-induced secretion of interluekin-6, an
inflammatory cytokine, in a concentration-dependent
manner.
Filep et al.15 Bolus i.v. injections of ET-1
(0.1e1 nmol kg1) were given
to anesthetized guinea pigs.
Albumin extravasation (quantified by Evan’s Blue due
binding) was observed in the trachea, upper bronchi,
and lower bronchi for each ET dose when compared
with control. The extravasation occurred in a dose-
dependent manner.
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Two subtypes of ET receptors are found in different loca-
tions (Table 2). ETA receptors are expressed on vascular
smooth muscle cells and fibroblasts, while ETB receptors
are located on vascular smooth muscle cells, endothelial
cells, fibroblasts, and macrophages. ET signaling through
the ETA receptor results in vasoconstriction, while the ETB
receptor can cause both vasodilation or vasoconstriction
(Fig. 1).16
The relative densities of the ETA and ETB receptors
vary between tissues and can be altered by disease.
Consequently, it is not possible to confidently infer the
net effects of ET-1 signaling simply on the basis of the
cell type or location. For example, in vitro autoradiog-
raphy of explanted lung tissue demonstrated that distal
pulmonary arteries from individuals without pulmonary
hypertension contained a ten-fold greater proportion of
ETB receptors than proximal arteries, indicating that the
ETA and ETB receptors are differentially distributed inhuman pulmonary arteries.17 Upregulation of ETB recep-
tors has also been demonstrated within the pulmonary
vasculature, interstitium, and airways of scleroderma
patients with pulmonary fibrosis.18 An increase in ETA
receptor density has been reported in the pulmonary
arteries and parenchyma of patients with congenital
heart disease.19 The expression of both ETB mRNA tran-
scripts and protein are increased in biopsy samples taken
from patients with thromboembolic PH as compared to
control lung tissue from donors without PH. By contrast,
ETA gene and protein expressions in these diseases tissues
were unchanged as compared to control.20 In other cases
it appears that the expression of both ET receptors can be
altered by disease, but without a concomitant change in
their relative densities. For example, despite a two-fold
increase in receptor in PAH patients relative to controls
and an associated increase in ligand binding, the relative
proportions of the ETA and ETA receptors on distal
pulmonary arteries were not altered within explanted
lung tissues.17
Table 2 Target organs for endothelin-1 (ET-1) action and
receptors involved.a
Target Organ Action Receptor
Heart
Coronary vasculature Vasoconstriction ETA (ETB)
Vasodilatation ETB
Cardiomyocyte Inotropy ETA (ETB)
Lung
Pulmonary artery Vasoconstriction ETA and ETB
Vasodilatation ETB
ET-1 clearance ETB
Kidney
Renal artery Vasoconstriction ETA
Vasodilatation ETB
Afferent arteriole Vasoconstriction ETA and ETB
Efferent arteriole Vasoconstriction ETA
Vasodilatation ETB
Cortical vasculature Vasoconstriction ETA
Medullary vasculature Vasodilatation ETB
Mesangial cell Contraction ETA
Brain
Cerebral vasculature Vasoconstriction ETA
Vasodilatation ETB
a Modified with permission from Ref. 64. Originally published
Trends Pharmacol Sci, volume 28, Dhaun N, Pollock DM,
Goodard J, et al, page 574, copyright Elsevier, 2007
Figure 2 A hypothetical model of endothelin-1 (ET-1)
binding to ETA receptors, ETB receptors and ETAeETB receptor
heterodimers.
Table 3 Selectivities of endothelin-1 receptor antagonists
(ERAs).
Ambrisentan Bosentan Sitaxsentan
ETA Ki (nM) 0.011 4.7 1.4
ETB Ki (nM) >44 95 9800
ETA:ETB >4000 20 7000
Half-life (hrs) 15.0 5.0 5.9e7.5 (rat)
Reference PI51 PI59 Wu et al.65
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The two ET-1 receptors exhibit somewhat different physio-
logical roles. ETA primarily mediates vasoconstriction and
proliferation. On smooth muscle cells, ETB mediates vaso-
constriction. ETB is also responsible for the removal of ET-1
from plasma.21 Activation of endothelial ETB receptors stim-
ulates the release of NO and prostacyclin,22 prevents
apoptosis,23 inhibits ECE-1 expression in endothelial cells and
plays a role in endothelial-dependent vasodilatation.24
ETB may play a role in ET-mediated inflammation. Binding
of ET-1 or the ETB-selective ET-3 to this receptor can induce
endothelial cell transcription of pro-inflammatory media-
tors.25 Incubation of cultured humanmonocytes with ETalso
induced expression of inflammatory cytokines (e.g., TNFa).
These cells expressed ETB and not ETA, and the effect was
inhibited by co-incubation of cells with bosentan, suggesting
the pro-inflammatory activity was mediated by ETB.
26
Cross-talk between ETA and ETB receptors
Multiple animal models suggest that significant cross-talk
occurs between the ETA and ETB receptors in certain
pathologic states.27 Such cross-talk might allow one
receptor to compensate for blockade of the other. For
example, the ETB receptor may adopt functions of the ETA
receptor under conditions of selective ETA blockade,
28
suggesting that in some cell systems the inhibition of both
receptors may be needed for maximum inhibition.27 The net
effect may be difficult to predict, however, as antagonism
of both receptors may have either additive or synergistic
effects compared with single receptor blockade.29Heterodimers with ETA and ETB receptors
The ETA and ETB receptors are G-protein coupled receptors
(GPCRs) belonging to the rhodopsin class A of seven trans-
membrane proteins.30 GPCR dimerization may be required
for the proper functioning of some receptors, such as the
GABAB receptor.
31 Even GPCRs that do not absolutely
require dimerization for functional activity may still asso-
ciate with other GPCR subtypes, which might alter receptor
pharmacology, signaling, or internalization. Indeed, heter-
odimerization may be an explanation for the cross-talk that
is observed in various signaling pathways.32 Another possi-
bility is that many GPCRs form constitutive dimers in the
endoplasmic reticulum and dimerization may be required
for trafficking to the cell surface.33
Functional heterodimers could be a possible explanation
for the pharmacologic complexity that has been observed
for the ETB receptor that cannot be accounted for by the
molecular structure of cloned receptors.34,35 Various lines
of evidence suggest that ETA and ETB can form functional
heterodimers (Fig. 2).36 The existence of heterodimers is
supported by the observation that ET-1 is a bivalent ligand,
which binds to the ETA receptor via its N terminus and to
the ETB receptor via its C terminus.
37 It has also been
suggested that functional heterodimers between ETA and
ETB could explain synergistic effects (to be described later)
sometimes observed when blocking both ETA and ETB
receptors.37
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The FDA-approved ERAs include bosentan which is a dual
inhibitor of both ETA and ETB, and ambrisentan which is an
ETA selective antagonist. Another ERA available for use in
PAH patients in Canada and Europe, sitaxsentan, is also an
ETA selective antagonist. Table 3 lists the selectivities,
binding constants, and terminal half-lives for these ERAs.
Selective blockers of either ETA (e.g. ambrisentan and
sitaxsentan) or ETB receptors have been developed and
used as tools in elucidating the physiological and patho-
logical roles of ET.38 In several animal models39,40 blocking
ETA alone has provided some blunting of physiologic ET
effects; however, little effect has been seen by blocking
the ETB receptor alone. In these models, maximum inhibi-
tion was observed with the blockade of both receptors.39,40
Human arterial vasoconstriction vs vasodilatation
Whether ETA or ETB antagonism results in arterial vaso-
constriction or vasodilatation appears to vary according to
the model system and vessels studied (Table 4). In human
internal mammary arteries and radial arteries, the ETB
receptor antagonist BQ-788 significantly inhibited ET-1-
induced contraction in internal mammary arteries, but not
in radial arteries.29 This was contrasted with the results
using the ETA receptor antagonist BQ-610, which produced
a much more potent inhibitory effect on ET-1-induced
contraction in internal mammary arteries and also potently
inhibited the contraction in radial arteries. The authors
concluded that ET-1-induced contraction is mediated by
both the ETA (major) and the ETB (minor) receptors in
internal mammary arteries, but only by the ETA receptor in
radial arteries.
A series of experiments on isolated small pulmonary
arteries from rats in which myocardial infarctions had been
induced showed that dual antagonism with specific ETA and
ETB receptor blockers resulted in optimal blockade of
vasoconstriction, possibly because the ETA and ETB recep-
tors could form functional heterodimers.41 Some studies
suggest that ETA and ETB receptor antagonism is compli-
mentary and that the results may be different for healthy
individuals compared with patients.42 In an investigation of
the possible role of ET-1 in the increased vasoconstrictor
tone of hypertensive patients, various antagonists of ET-1
receptors were applied via intraarterial infusion (ETA
receptor antagonist [BQ-123] and ETB receptor antagonist
[BQ-788]). In healthy subjects, BQ-123 alone or in combi-
nation with BQ-788 did not significantly modify forearm
blood flow. In hypertensive patients, in contrast, BQ-123
increased forearm blood flow and the combination of BQ-
123 and BQ-788 resulted in a greater vasodilator response vs
BQ-123 alone. These results suggest that both ETA and ETB
receptor blockade result in more marked vasodilation
(measured by forearm blood flow) in hypertensive patients
compared with selective ETA receptor blockade. Other
studies suggest that ETA and ETB receptor antagonism is
synergistic and that combined ETA/ETB receptor antago-
nism is required for complete inhibition of ET-1-induced
pulmonary artery vasoconstriction in a rat model of PH
(isolated perfused rat lungs).39 The application of theseobservations in the pulmonary circulation of patients with
PAH remains unclear.
Remodeling
A number of studies have examined the effects of specific
ETA vs ETB receptor antagonists on properties related to
remodeling. Incubation of normal human dermal fibroblasts
with ET resulted in the induction of type I collagen synthesis
and a decrease in interstitial collagenase expression.43 ETA
blockade normalized collagenase levels, but did not affect
the overproduction of collagen. On the other hand, ETB
blockade did not affect induction of type I collagen
synthesis or interstitial collagenase expression. Both ETA
and ETB mediate the proliferation-inducing effects of ET-1
on cultured pulmonary artery smooth muscle cells derived
from explanted human lung.17
ETA/ETB receptor antagonism
Blockers have been developed that are antagonists of both
ETA and ETB receptors (e.g. bosentan) and are considered
dual ET antagonists.
Human arterial vasoconstriction vs vasodilatation
In studies of saphenous vein segments, application of
bosentan induced in vitro vasodilation (Table 5).44 Bosen-
tan (3 mM) significantly augmented acetylcholine (ACh)-
induced vasodilation in pre-contracted isolated saphenous
vein segments; however, no response was observed in
veins denuded of endothelium. Consequently, blockade of
ETA/ETB significantly improved endothelial cell-mediated
dilation by ACh in saphenous veins.
Remodeling
In a porcine model of PAH (overcirculation-induced model of
PAH produced by anastomosis of the left subclavian artery to
the pulmonary arterial trunk) and congenital heart disease
(CHD), bosentan prevented pulmonary artery changes
indicative of remodeling.45 Bosentan prevented medial
thickening, most evident in the smallest arterioles and pre-
vented medial changes associated with overcirculation.
In a rat model of hypoxia-induced PH, bosentan prevents
and reverses vascular hypertrophy.46 Pulmonary artery
pressures were nearly returned to control levels, and
hypoxia-induced morphological changes within the pulmo-
nary vascular bed regressed. In other experiments,
pretreatment with bosentan prevented the development of
hypoxia-induced PH. There was complete blockade of the
acute pulmonary vasoconstrictor response to acute
hypoxia, the chronic hypoxia-induced PH, and pulmonary
vascular remodeling. At the same time, there was no effect
on systemic arterial pressure.
Inflammation
Bosentan inhibits inflammation in a rat model in which the
intratracheal instillation of Sephadex dissolved in saline
produces a hypersensitivity reaction and the rapid
Table 4 Effects of ETA vs ETB antagonism.
Effect Reference Study design Result
Vasoconstriction vs
vasodilation
Liu et al.29 The effects of various ET
antagonists and agonists were
examined in an in vitro
preparation (human radial
arteries and internal mammary
arteries).
The ETB antagonist BQ-788
significantly inhibited ET-1-
induced contraction in internal
mammary arteries, but not in
radial arteries. The ETA
receptor antagonist BQ-610
inhibited ET-1-induced
contraction in both internal
mammary arteries and radial
arteries. In the internal
mammary artery, combination
ETA/ETB blockade might be
more effective than ETA alone.
Cardillo et al.42 Forearm blood flow responses
were measured using strain-
gauge plethysmography after
intraarterial infusion of
blockers of ETA [BQ-123] and
ETB [BQ-788] receptors in both
volunteers and hypertensive
patients.
In healthy subjects, BQ-123
alone or in combination with
BQ-788 did not significantly
modify forearm blood flow. In
hypertensive patients, in
contrast, BQ-123 significantly
increased forearm blood flow,
and the combination of BQ-123
and BQ-788 resulted in a
greater vasodilator response.
Thus, both ETA and ETB
receptor blockade resulted in
more marked vasodilation
(measured by forearm blood
flow) in hypertensive patients
compared with selective ETA
receptor blockade.
Furthermore, this effect was
not observed in healthy
volunteers.
Sato et al.39 The effects of ET-receptor
agonists and antagonists were
studied in isolated perfused rat
lungs.
In the isolated perfused rat
lung, ET-1-induced
vasoconstriction was mediated
by both ETA and ETB receptors,
whereas ET-1-induced
transient vasodilation is
mediated exclusively by the
ETB receptor. Blockade of ETB
receptors may have resulted in
enhanced ET-1 activity (via the
ETA receptor) through
inhibition of the ETB-mediated
clearance of ET-1. Thus
combined ETA and ETB blockade
was required for the complete
inhibition of ET-1-induced
vasoconstriction in the rat
pulmonary circulation.
Endothelin receptor blockade 957recruitment of inflammatory cells, an increase in ET and
cytokine secretion.47 Rats pre-treated with bosentan showed
markedly attenuated Sephadex-induced peribronchial
inflammation.ETA vs ETA/ETB receptor antagonism
Several studies have examined the effects of selective ETA
antagonism compared with dual ETA/ETB antagonism
Table 5 Effects of ET antagonism with ETA/ETB antagonism.
Effect Reference Study design Result
Vasoconstriction vs
vasodilation
Dumont et al.44 ACh-induced vasodilation was
studied in vascular segments of
saphenous vein that were
obtained in 34 patients.
Bosentan (3 mM) significantly
increased ACh-induced
vasodilation in pre-contracted
isolated saphenous vein
segments. No response was
observed in veins denuded of
endothelium. Thus blockade of
ETA/ETB significantly improved
endothelial cell-mediated
dilation by ACh in saphenous
veins.
Remodeling Chen et al.46 Rats with established chronic
hypoxic (10% oxygen) PH were
studied.
Bosentan reversed hypoxic PH,
returned PAP nearly to control
levels, and caused regression of
hypoxia-induced morphological
changes in the pulmonary
vascular bed. Pretreatment
with bosentan prevented the
development of hypoxia-
induced PH.
Rondelet et al.45 In a porcine overcirculation-
induced model of PAH
(anastomosis of the left
subclavian artery to the
pulmonary arterial trunk),
pulmonary arteries were
examined for medial
hypertrophy.
Bosentan prevented medial
thickening, most evident in the
smallest arterioles. This
normalization of the medial
layer of vessels suggests that
bosentan prevented the
changes associated with
overcirculation in this model.
Shi-Wen et al.43 Human dermal fibroblasts were
incubated with ET in an in vitro
cell culture.
Incubation with ET resulted in
induction of type I collagen
synthesis and decrease in
interstitial collagenase
expression. Bosentan showed
anti-fibrotic effects by
abolishing the ET-induced
increase in collagen secretion
and the ET-induced decrease in
collagenase synthesis.
Inflammation Finsnes et al.47 In the rat inflammatory airway
model, Sephadex was dissolved
in saline and given
intratracheally. Rats have a
natural hypersensitivity to
dextran, resulting in a rapid
recruitment of inflammatory
cells around the Sephadex
beads and an increase in ET and
cytokine secretion.
Rats pre-treated with bosentan
showed markedly reduced
Sephadex-induced
peribronchial inflammation.
958 T.K. Trow, D.B. Taichman(Table 6). In isolated perfused rat lungs, dual ETA and ETB
receptor antagonism inhibited ET-1-induced pulmonary
vasoconstriction to a greater extent than ETA receptor
blockade alone.39In some experimental conditions, ETA and ETB receptor
antagonism appears to be complimentary.40 In a mono-
crotaline-induced model of PH in rats, survival was greater
among animals treated with a dual ETA/ETB receptor
Table 6 Effects of ETA vs ETA/ETB antagonism.
Effect Reference Study design Result
Survival Jasmin et al.40 Rats with
monocrotaline-induced
pulmonary
hypertension received an
ETA selective (LU135252)
or nonselective
(BSF420627) antagonist
for 3 weeks.
Survival was significantly
greater for animals
treated with the dual
ERA than
control. A considerably
less marked effect
on survival was observed
with only ETA selective
blockade.
This suggests that
blockade of both ETA and
ETB receptors is required
to inhibit the deleterious
effects of ET-1 in this
animal model of PH.
Endothelin receptor blockade 959antagonist than an ETA-specific inhibitor. Reduction of right
ventricular hypertrophy was seen only in the animals
receiving the dual antagonist, suggesting that blockade of
both ETA and ETB receptors in rat is required to fully inhibit
the deleterious effects of ET-1 in this monocrotaline model.
The implications of these experimental findings in human
disease, however, are unclear.
Pivotal clinical trials of ERAs
FDA approval of bosentan for the treatment of PAH came
from 2 randomized, placebo-controlled trials of patients
with PAH functional class (FC) III or IV; for both studies, the
primary endpoint was the degree of change in exercise
capacity. In Study 351, Channick et al. reported a 76-m
improvement in 6 min walk distance (6MWD) with bosentan
(nZ 21) compared with placebo (nZ 10) (PZ 0.021) and
significant improvements in mean pulmonary artery pres-
sure, cardiac index, and peripheral vascular resistance
(P 0.033) as well as both FC (P 0.019) and the time to
clinical worsening (PZ 0.033).48 In the BREATHE-1 (Bosen-
tan Randomized Trial of Endothelial Antagonist Therapy of
Pulmonary Hypertension) trial, patients treated with
bosentan (nZ 144) had a 44-m improvement in 6MWD
compared with those in the placebo group (nZ 69)
(P< 0.001).49 Bosentan also significantly increased the time
to clinical worsening (P< 0.002) and improved FC (P-value
not given).
FDA approval for ambrisentan came from 2 randomized,
double-blind, placebo-controlled trials of patients with
PAH (WHO Group I): ARIES-1 (Ambrisentan in PAH) and
ARIES-2, both of which had 6MWD as the primary
endpoint.50 In ARIES-1, which compared once-daily doses
of 5 mg and 10 mg of ambrisentan to placebo, the placebo-
adjusted mean change in 6MWD from baseline was 51 m
(P< 0.001) for the 10-mg group and 31 m (PZ 0.008) for
the 5-mg group. In ARIES-2, which compared once-daily
doses of 2.5 mg and 5 mg ambrisentan to placebo, the
placebo-adjusted mean change in 6MWD from baseline was
59 m (P< 0.001) for the 5-mg group and 32 m (PZ 0.022)for the 2.5-mg group. Functional class was improved from
baseline in ARIES-1 compared to placebo (PZ 0.036) and
while similar trends were seen in functional class
improvement in ARIES-2 these were not statistically
significant (PZ 0.117). When combined data for the 5 mg
dose from ARIES-1 and ARIES-2 were analyzed WHO func-
tional class improvement from baseline to week 12 was
observed (PZ 0.025), mostly as a result of less functional
class deterioration with ambrisentan as compared to
placebo. In ARIES-2, improvements in time to clinical
worsening compared to placebo were observed for the 5-
mg group (PZ 0.008) and 2.5-mg group (PZ 0.005). In
ARIES-1, time to clinical worsening did not significantly
improve compared to placebo. When these two datasets
were combined as adjudicated by the FDA, time to clinical
worsening was judged to be significantly improved
compared to placebo.51
The randomized, double-blind, placebo-controlled trials
of sitaxsentan are the STRIDE-152 and STRIDE-253 (Sitax-
sentan To Relieve ImpaireD Exercise) trials. In STRIDE-1,
300 mg of sitaxsentan increased the VO2 max of PAH
patients by 3.1% as compared with placebo by 12 weeks of
treatment; both 100 mg and 300 mg treatments resulted in
33e35 m improvements in 6MWD, as well as improvements
in hemodynamic indices and functional class.52 In STRIDE-2,
treatment of PAH patients with 50 and 100 mg of sitaxsen-
tan resulted in 24 and 31 m increases in 6MWD at 18
weeks.53
For all three agents, limited information is known about
potential drugedrug interactions which might affect their
utility. Studies of interactions with warfarin suggest that
warfarin levels are modestly reduced in the presence of
bosentan, increased in the presence of sitaxsentan, and
appear unaltered in the presence of ambrisentan. Silde-
nafil levels appear reduced in the presence of bosentan
but unaltered by ambrisentan. It should be noted,
however, that studies of bosentan’s interaction with sil-
denafil have been conducted in healthy volunteers who did
not suffer from chronic cardiac, hepatic, or renal insuffi-
ciency. Other interactions require more vigorous
investigation.
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This review of the literature shows that the results of ETA,
ETB, or dual ETA/ETB receptor blockade can be different
under normal physiological conditions compared with
pathological conditions. Arguments have been put forward
to support an advantage of each ETA or dual ETA/ETB
receptor blockade.
Cross-talk between ETA and ETB raises the possibility
that blockade of both receptors may be required for
maximum inhibition in some instances. Theoretically, ETA
and ETB receptor antagonism may be complimentary or
synergistic. Furthermore, in some animal models, survival
benefits have been observed for dual ETA/ETB blockade
compared to single ET-receptor blockade.
The major argument theoretically favoring selective ETA
blockade is that ETB is involved in clearing ET-1 from the
circulation. Consequently, blocking ETB receptors might be
expected to increase plasma ET-1 levels and worsen the
symptoms of PAH. In addition, blockade of endothelial
luminal side ETB might theoretically decrease NO and
prostacyclin production. However, it is important to note
that circulating levels of ET-1 may not directly reflect the
abluminal paracrine action of ET-1 on smooth muscle cells
that is felt to be of primary importance.
Neither argument has yet been tested nor supported by
available clinical trial evidence. A review of the clinical
trial data indicates that there are no apparent differences
in measurable clinical efficacy among the various single and
dual ERAs.54 Head-to-head studies, particularly in different
pathological conditions, will be necessary to definitively
answer the question whether there are long-term efficacy
differences between single and dual ERAs.
There are safety differences between dual and selective
ERAs with regard to the development of liver function test
abnormalities. Liver aminotransferase level elevations are
more common with bosentan than with sitaxsentan and
ambrisentan.55 However, post-marketing surveillance
studies of bosentan reveal that permanent or fatal liver
damage has not been observed.56,57
The use of ERAs can result in the development of wors-
ening of peripheral edema in some patients.58 In renal
mesangial cells, ET-1 produces natriuresis and diuresis via
ETA and ETB; therefore, ERAs could cause edema.
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However, the incidence of edema during ERA therapy seems
to be correlated with both the selectivity and dosage of the
ERA. The incidence of peripheral edema was 8% in pivotal
trials of bosentan, compared to 5% in placebo patients.59
Peripheral edema was a commonly reported adverse event
in the ARIES trials, with an incidence of 28.4% in the 10-mg
group of the ARIES-1 study (compared to 10.6% in the
placebo group).50 When data from the two trials are
combined, overall edema rates of 17% were seen in contrast
to 11% in the placebo arm.51 Rates also appear to be
greatest for the elderly in these trials, with those >65 years
of age demonstrating a 29% incidence of edema vs 4% for
placebo patients. The STRIDE-1 study reported the
following rates of peripheral edema: placebo, 16%; sitax-
sentan 100 mg, 17%; and sitaxsentan 300 mg, 25%.52 In
STRIDE-2, the rates of edema were 8.1% for placebo and
sitaxsentan 50 mg, and 11.5% for sitaxsentan 100 mg.53In comparing these rates of peripheral edema it is
important to recognize, however, that each of these trials
(BREATHE-1, ARIES, STRIDE) studied different populations
with fewer patients over the age of 65 being studied in the
BREATH-1 trial. In addition the trials did not take into
account concomitant medications or medical conditions
making it difficult to compare these agents in regards to
side-effect profiles. As such, firm statements regarding
relative frequency of important side effects cannot be
made.
If indeed an increased rate of peripheral edema turns
out to be more common with ambrisentan than with
bosentan or sitaxsentan, one possible explanation for
different rates of edema associated with ERAs may not be
related to differences in selectivities for the two ET
receptors, but instead may reflect differences in affinities
to the ETA receptor. According to Table 3, the ERAs in
order of affinity to the ETA receptor are ambri-
sentan> sitaxsentan> bosentan. When one looks at
another GPCR, the dopamine D2 receptor, differences in
affinity of atypical antipsychotics in binding to the D2
receptor have been related to their propensity to produce
side effects. It has been hypothesized that atypical anti-
psychotics that bind more loosely to the dopamine D2
receptor (e.g., quetiapine, KiZ 140 nM) are less likely to
produce side effects such as motor symptoms or hyper-
prolactinemia than atypical antipsychotics that bind more
tightly (e.g., risperidone, KiZ 1.1 nM compared to a Ki
value for dopamine of 1.7 nM).60 The hypothesis is that
dopamine released as a neurotransmitter can readily
displace quetiapine but not risperidone from D2 receptors
and thus quetiapine is less likely to produce side effects.
Similar mechanisms could be occurring in peripheral
vascular beds, with bosentan more easily displaced by ET-1
than ambrisentan at ETA receptors, thus resulting in a lower
incidence of edema with bosentan.
A potential explanation for the different rates of edema
with selective vs dual ERAs may involve the renineangio-
tensin system. A recent study suggested that the effects of
endothelin receptor blockade, beneficial or harmful, may
crucially depend on the stage of congestive heart failure
(CHF) when therapy is initiated.61 This study also reported
that selective ETA receptor blockade during an early stage
of CHF caused sustained Naþ retention by activating the
renineangiotensin system and resulted in edema. Thus,
selective ETA blockade might be more likely to produce
edema in some patients at certain stages of their disease.
Other theoretical reasons for different edema tendencies
might be in differences in the interactions of the agents
with aldosterone and mineralocorticoid receptors,62 and
unstudied interactions with aquaporin-2 and aquaporin-3.63
Although these mechanisms have been suggested as possi-
bilities, the exact mechanisms for the potential different
rates of edema among the ERAs are not known at this time.
There are several caveats that must be offered for the
results reported here. Supporting evidence from animal
studies may not accurately reflect the physiology of humans
in health and disease. In addition, results observed for ET-
receptor blockade in one region of the body may not be
applicable to another region. In vitro findings in contrived
experimental models may not offer fidelity to the clinical
state of PAH. Finally, results observed under normal
Endothelin receptor blockade 961conditions may not be applicable to pathological conditions
and visa versa.
In conclusion, ET receptors have different densities and
distributions throughout the body, which are dynamically
up- and down-regulated in a still not-adequately-studied
manner, and blockade of ETA and ETB receptors may render
different results in normal vs pathological conditions.
Clinical trial data do not indicate any apparent differences
in short-term efficacy between dual and single ET-receptor
blockade. Dual blockade appears less likely to produce
edema as a side effect, although the elderly population
allowed in ARIES-1 and ARIES-2 was not studied in either of
the double-blind, placebo-controlled trials of bosentan
making definitive statements about edema prevalence
between the agents tenuous. In addition these trials did not
control for associated disease states or medications that
might have altered the presence of edema. Dual blockade
appears more likely to induce LFT abnormalities. Head-to-
head studies will be required to completely answer these
questions of relative efficacy and relative safety profiles of
single vs dual ERAs.
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